Report on 2012 ISN nexus symposium: 'Bone and the kidney'

Kidney International

Volumn 83, Issue 4, 2013, Pages 557-562

  Drüeke, Tilman B ^a   Olgaard, Klaus ^b  

^a INSERM   (France)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

chronic kidney disease; hyperparathyroidism; osteodystrophy; phosphate; vascular calcification; vitamin D

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; C REACTIVE PROTEIN; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MAGNESIUM; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE;

ABSORPTION; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CATABOLISM; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DECARBOXYLATION; HEMATOPOIESIS; HOMEOSTASIS; HUMAN; MEDICAL SOCIETY; MINERAL DEFICIENCY; MINERALIZATION; NONHUMAN; PATHOGENESIS; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SYMPOSIUM;

EID: 84875702303     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.453     Document Type: Conference Paper

References (74)

1. Kuro-o M. Klotho in health and disease. Curr Opin Nephrol Hypertens 2012; 21: 362-368.
2. Razzaque MS. FGF23, klotho and vitamin D interactions: hat have we learned from in vivo mouse genetics studies? Adv Exp Med Biol 2012; 728: 84-91.
3. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012; 92: 131-155.
4. Drueke TB. Klotho, FGF23, and FGF receptors in chronic kidney disease: a yin-yang situation? Kidney Int 2010; 78: 1057-1060.
5. Moe OW. Fibroblast growth factor 23: friend or foe in uremia? J Clin Invest 2012; 122: 2354-2356.
6. Bacchetta J, Sea JL, Chun RF et al. FGF23 inhibits extra-renal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 2012; 28: 46-55.
7. Olauson H, Lindberg K, Amin R et al. Targeted deletion of klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol 2012; 23: 1641-1651.
8. Seiler S, Wen M, Roth HJ et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2013; 83: 121-128.
9. Woudenberg-Vrenken TE, van der Eerden BC, van der Kemp AW et al. Characterization of vitamin D-deficient klotho-/-mice: do increased levels of serum 1,25(OH)2D3 cause disturbed calcium and phosphate homeostasis in klotho-/-mice? Nephrol Dial Transplant 2012; 27: 4061-4068.
10. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122: 2543-2553.
11. Jean G, Bresson E, Lorriaux C et al. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. Nephron Clin Pract 2012; 120: c132-c138.
12. Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation Kidney Int 2012; 81: 640-650.
13. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136.
14. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
15. Komaba H, Fukagawa M. The role of FGF23 in CKD-with or without Klotho. Nat Rev Nephrol 2012; 8: 484-490.
16. Lim K, Lu TS, Molostvov G et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125: 2243-2255.
17. Bhattacharyya N, Chong WH, Gafni RI et al. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab 2012; 23: 610-618.
18. Devarajan-Ketha H, Craig TA, Madden BJ et al. The sclerostin-bone protein interactome. Biochem Biophys Res Commun 2012; 417: 830-835.
19. Drueke TB, Lafage-Proust MH. Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 2011; 6: 700-703.
20. Kumar R. Phosphate sensing. Curr Opin Nephrol Hypertens 2009; 18: 281-284.
21. Marks J, Debnam ES, Unwin RJ. Phosphate homeostasis and the renalgastrointestinal axis. Am J Physiol Renal Physiol 2010; 299: F285-F296.
22. Sabbagh Y, O'Brien SP, Song W et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 2009; 20: 2348-2358.
23. Schiavi SC, Tang W, Bracken C et al. Npt2b Deletion Attenuates Hyperphosphatemia Associated with CKD. J Am Soc Nephrol 2012; 23: 1691-1700.
24. Martuseviciene G, Hofman-Bang J, Clausen T et al. The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-ATPase activity. Kidney Int 2011; 79: 742-748.
25. Silver J, Rodriguez M, Slatopolsky E. FGF23 and PTH-double agents at the heart of CKD. Nephrol Dial Transplant 2012; 27: 1715-1720.
26. Grant MP, Stepanchick A, Cavanaugh A et al. Agonist-driven maturation and plasma membrane insertion of calcium-sensing receptors dynamically control signal amplitude. Sci Signal 2011; 4: ra78.
27. Hofman-Bang J, Martuseviciene G, Santini MA et al. Increased parathyroid expression of klotho in uremic rats. Kidney Int 2010; 78: 1119-1127.
28. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77: 232-238.
29. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218.
30. Muteliefu G, Shimizu H, Enomoto A et al. Indoxyl sulfate promotes vascular smooth muscle cell senescence with upregulation of p53, p21, and prelamin A through oxidative stress. Am J Physiol Cell Physiol 2012; 303: C126-C134.
31. Mozar A, Louvet L, Godin C et al. Indoxyl sulphate inhibits osteoclast differentiation and function. Nephrol Dial Transplant 2012; 27: 2176-2181.
32. Meijers BK, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011; 26: 759-761.
33. Naveh-Many T. Minireview: the play of proteins on the parathyroid hormone messenger ribonucleic Acid regulates its expression. Endocrinology 2010; 151: 1398-1402.
34. Nechama M, Uchida T, Mor Yosef-Levi I et al. The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism. J Clin Invest 2009; 119: 3102-3114.
35. Arcidiacono MV, Sato T, Alvarez-Hernandez D et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol 2008; 19: 310-320.
36. Dusso A, Arcidiacono MV, Yang J et al. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 2010; 121: 193-198.
37. Dimke H, Hoenderop JG, Bindels RJ. Molecular basis of epithelial Ca2\+ and Mg2\+ transport: insights from the TRP channel family. J Physiol 2011; 589(Pt 7): 1535-1542.
38. de Groot T, Bindels RJ, Hoenderop JG. TRPV5: an ingeniously controlled calcium channel. Kidney Int 2008; 74: 1241-1246.
39. Ferre S, Hoenderop JG, Bindels RJ. Insight into renal Mg2\+ transporters. Curr Opin Nephrol Hypertens 2011; 20: 169-176.
40. Chaudhary DP, Sharma R, Bansal DD. Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res 2010; 134: 119-129.
41. Nair AV, Hocher B, Verkaart S et al. Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. Proc Natl Acad Sci USA 2012; 109: 11324-11329.
42. Ferre S, Hoenderop JG, Bindels RJ. Sensing mechanisms involved in Ca(2\+) and Mg(2\+) homeostasis. Kidney Int 2012; 82: 1157-1166.
43. Loupy A, Ramakrishnan SK, Wootla B et al. PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest 2012; 122: 3355-3367.
44. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26: 229-238.
45. Sabbagh Y, Graciolli FG, O'Brien S et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012; 27: 1757-1772.
46. Karsenty G, Oury F. Biology without walls: the novel endocrinology of bone. Annu Rev Physiol 2012; 74: 87-105.
47. Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature 2012; 481: 314-320.
48. Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469.
49. Lafage-Proust MH, Prisby R, Roche B et al. Bone vascularization and remodeling. Joint Bone Spine 2010; 77: 521-524.
50. Prisby R, Guignandon A, Vanden-Bossche A et al. Intermittent PTH(1-84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites. J Bone Miner Res 2011; 26: 2583-2596.
51. Ott SM. Bone disease in CKD. Curr Opin Nephrol Hypertens 2012; 21: 376-381.
52. Yenchek RH, Ix JH, Shlipak MG et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 2012; 7: 1130-1136.
53. Nickolas TL, Stein E, Cohen A et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 2010; 21: 1371-1380.
54. Mazzaferro S, Pasquali M, Rotondi S et al. Does any therapy exist for vascular calcifications in uremia? J Nephrol 2011; 24(Suppl 18): S16-S24.
55. Marckmann P, Agerskov H, Thineshkumar S et al. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 2012; 27: 3523-3531.
56. Qiu N, Xiao Z, Cao L et al. Conditional mesenchymal disruption of pkd1 results in osteopenia and polycystic kidney disease. PLoS One 2012; 7: e46038.
57. Qiu N, Xiao Z, Cao L et al. Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. J Cell Sci 2012; 125(Pt 8): 1945-1957.
58. Kapustin AN, Shanahan CM. Calcium regulation of vascular smooth muscle cell-derived matrix vesicles. Trends Cardiovasc Med 2012; 22: 133-137.
59. Ketteler M, Rothe H, Kruger T et al. Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 2011; 7: 509-516.
60. Rezg R, Barreto FC, Barreto DV et al. Inhibitors of vascular calcification as potential therapeutic targets. J Nephrol 2011; 24: 416-427.
61. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010; 7: 528-536.
62. Fusaro M, Noale M, Viola V et al. Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study. J Bone Miner Res 2012; 27: 2271-2278.
63. Schurgers LJ, Joosen IA, Laufer EM et al. Vitamin k-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One 2012; 7: e43229.
64. Cranenburg EC, Schurgers LJ, Uiterwijk HH et al. Vitamin K intake and status are low in hemodialysis patients. Kidney Int 2012; 82: 605-610.
65. Westenfeld R, Krueger T, Schlieper G et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis 2012; 59: 186-195.
66. Chen NX, Kircelli F, O'Neill KD et al. Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells. Kidney Int 2010; 77: 436-442.
67. Warren DT, Shanahan CM. Defective DNA-damage repair induced by nuclear lamina dysfunction is a key mediator of smooth muscle cell aging. Biochem Soc Trans 2011; 39: 1780-1785.
68. Hamano T, Matsui I, Mikami S et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 2010; 21: 1998-2007.
69. Pasch A, Farese S, Graber S et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012; 23: 1744-1752.
70. Chen NX, Moe SM. Vascular calcification: pathophysiology and risk factors. Curr Hypertens Rep 2012; 14: 228-237.
71. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415.
72. Drueke TB, Massy ZA. Phosphate binders in CKD: bad news or good news? J Am Soc Nephrol 2012; 23: 1277-1280.
73. Chertow GM, Correa-Rotter R, Block GA et al. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrol Dial Transplant 2012; 27: 2872-2879.
74. The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494.